Pharsight

Truvada generic

Truvada is an antiretroviral medication owned by Gilead. It contains two active ingredients - Emtricitabine and Tenofovir Disoproxil Fumarate. The drug was authorised for market use on 02 August 2004 and is available in tablet form for oral administration. Truvada holds a total of four patents, none of which have expired as of now.

When will Truvada generic be available?

The generics of Truvada are expected to be released after 13 January 2024. This is due to the expiration of the drug's last patent (US8716264), titled 'Compositions and methods for combination antiviral therapy'. Therefore, patients can expect a cost-effective substitute for Truvada not before 2024.

Truvada uses

Truvada is used for the treatment of HIV infection. It is effective for both adults and pediatric patients who are older than 12 years. The active ingredients of Truvada, Emtricitabine and Tenofovir Disoproxil Fumarate, can decrease the amount of HIV in the body, help the immune system work better, and reduce the chances of getting HIV diseases. Additionally, Truvada is used for combination antiviral therapy.

Truvada patent expiration

Truvada's last patent (US8716264) which deals with 'Compositions and methods for combination antiviral therapy' is due to expire on 13 January 2024. Until then, the production of Truvada generics will be restricted. Below are the details of the patent:

EPO Oppostions filed on Truvada

Truvada dosage

Want to ask something?